Rapid CAR-T manufacturing and challenges in this space

Nina Worel, MD, Medical University of Vienna, Vienna, Austria, shares some insights into challenges with CAR-T manufacturing, explaining that even rapid manufacturing processes may require patients to wait up to four weeks before they can receive treatment. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.